Nanobiotix Enters License Agreement With Janssen Pharmaceutical For Worldwide Co-Development And Commercialization Of Potential First-In-Class Radioenhancer NBTXR3
Portfolio Pulse from Benzinga Newsdesk
Nanobiotix has entered into a license agreement with Janssen Pharmaceutical for the worldwide co-development and commercialization of potential first-in-class radioenhancer NBTXR3.
July 10, 2023 | 6:19 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Janssen Pharmaceutical, a subsidiary of Johnson & Johnson, has entered into a partnership with Nanobiotix for the co-development and commercialization of NBTXR3.
The partnership with Nanobiotix for the co-development and commercialization of NBTXR3 could potentially lead to a new revenue stream for Janssen Pharmaceutical and its parent company, Johnson & Johnson. This could have a positive impact on JNJ's stock in the short term.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
Nanobiotix has entered into a partnership with Janssen Pharmaceutical for the co-development and commercialization of NBTXR3.
The partnership with Janssen Pharmaceutical for the co-development and commercialization of NBTXR3 could potentially lead to a significant revenue stream for Nanobiotix. This could have a positive impact on NBTX's stock in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100